Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.68 |
| ▸ | POLB | P06746 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.61 |
| ▸ | MEN1 | O00255 | 2/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.61 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | HCRTR1 | O43613 | 4/20 | 0.53 |
| ▸ | HCRTR2 | O43614 | 4/20 | 0.53 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2707116 | 1.00 | NPSR1 (0.69) | NPSR1LMNANPC1POLBALDH1A1 | |
| SCHEMBL23559008 | 0.89 | NPSR1 (0.70) | NPSR1LMNANPC1POLBALDH1A1 | |
| SCHEMBL4101103 | 0.85 | NPSR1 (0.66) | NPSR1LMNANPC1POLBALDH1A1 | |
| SCHEMBL2389717 | 0.84 | NPC1 (0.77) | NPSR1LMNANPC1POLBALDH1A1 | |
| SCHEMBL17474759 | 0.84 | NPC1 (0.80) | NPSR1LMNANPC1ALDH1A1MEN1 | |
| SCHEMBL17474788 | 0.84 | NPC1 (0.80) | NPSR1LMNANPC1ALDH1A1MEN1 | |
| SCHEMBL2525285 | 0.84 | NPC1 (0.77) | NPSR1LMNANPC1POLBALDH1A1 | |
| SCHEMBL17474775 | 0.84 | NPC1 (0.69) | NPSR1LMNANPC1POLBALDH1A1 | |
| SCHEMBL23373363 | 0.83 | NPC1 (0.79) | NPSR1LMNANPC1ALDH1A1MEN1 | |
| SCHEMBL29639973 | 0.82 | NPC1 (0.71) | NPSR1LMNANPC1POLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2608787-B1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2019-11-20 | — | — | EP | disclosed |
| US-9211279-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-12-15 | — | — | US | disclosed |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-09-03 | — | — | US | disclosed |
| US-9000029-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2015-04-07 | — | — | US | disclosed |
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | IDORSIA PHARMACEUTICALS LTD (CH) | 2015-02-26 | — | — | US | disclosed |
| US-8895606-B2 | Proline sulfonamide derivatives as orexin receptor antagonists | ACTELION PHARMACEUTICALS LTD. (CH) | 2014-11-25 | — | — | US | disclosed |
| EP-2608787-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | Actelion Pharmaceuticals Ltd. (CH) | 2013-07-03 | — | — | EP | disclosed |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD. (CH) | 2013-06-13 | — | — | US | disclosed |
| WO-2012025877-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | ACTELION PHARMACEUTICALS LTD (CH) | 2012-03-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150057328-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | NPSR1 3/4885LMNA 3213/4885NPC1 994/4885 |
| US-20130150424-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | NPSR1 3/4885LMNA 3213/4885NPC1 994/4885 |
| US-20150246021-A1 | PROLINE SULFONAMIDE DERIVATIVES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPSR1 | NPSR1 3/4885LMNA 3255/4885NPC1 902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.